NASDAQ:MYOK - Myokardia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$52.61 -1.21 (-2.25 %)
(As of 03/18/2019 09:27 AM ET)
Previous Close$53.82
Today's Range$52.08 - $54.6296
52-Week Range$39.01 - $67.79
Volume1.16 million shs
Average Volume610,530 shs
Market Capitalization$2.12 billion
P/E Ratio-29.89
Dividend YieldN/A
Beta2.47
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a collaboration with 23andMe, Inc. to advance research for patients with hypertrophic cardiomyopathy. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$9.20 per share

Profitability

Net Income$-67,570,000.00
Net Margins-201.81%

Miscellaneous

EmployeesN/A
Market Cap$2.12 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Myokardia (NASDAQ:MYOK) Frequently Asked Questions

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings results on Thursday, February, 28th. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.07. Myokardia had a negative net margin of 201.81% and a negative return on equity of 20.00%. View Myokardia's Earnings History.

When is Myokardia's next earnings date?

Myokardia is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Myokardia.

What price target have analysts set for MYOK?

10 Wall Street analysts have issued 1 year price targets for Myokardia's shares. Their forecasts range from $70.00 to $90.00. On average, they anticipate Myokardia's stock price to reach $76.50 in the next year. This suggests a possible upside of 45.4% from the stock's current price. View Analyst Price Targets for Myokardia.

What is the consensus analysts' recommendation for Myokardia?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia.

What are Wall Street analysts saying about Myokardia stock?

Here are some recent quotes from research analysts about Myokardia stock:
  • 1. According to Zacks Investment Research, "MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. " (3/5/2019)
  • 2. Cantor Fitzgerald analysts commented, ": Reiterate OW and $90 PT. 6-month open label data on mavacamten continues to look clean around dosing safety. Although a small cohort, these data reinforce our confidence in dosing safety in Ph3 EXPLORER. At current levels, we think that potential mavacamten opportunity remains unappreciated. We estimate 2027 unadjusted US sales of $1.7B, which assumes 45k (obstructive and non-obstructive) patients are treated. From our recent meetings on the road, we think that interest and awareness are rising in the MYOK story. We spoke to the full team post call and highlight our takes below. Open-label mavacamten data in 10 patients at 6 months reinforces our confidence in Ph3 success." (3/4/2019)

Has Myokardia been receiving favorable news coverage?

News headlines about MYOK stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myokardia earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Myokardia's key competitors?

What other stocks do shareholders of Myokardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Chipotle Mexican Grill (CMG), Endologix (ELGX), Viper Energy Partners (VNOM), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA) and CVS Health (CVS).

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)
  • Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)
  • Dr. Charles J. Homcy, Advisor (Age 71)
  • Dr. Eric J. Topol, Advisor (Age 65)

Who are Myokardia's major shareholders?

Myokardia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (7.11%), Partner Fund Management L.P. (3.82%), Perceptive Advisors LLC (2.67%), BB Biotech AG (2.18%) and D. E. Shaw & Co. Inc. (2.15%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia.

Which institutional investors are selling Myokardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Millennium Management LLC, Lord Abbett & CO. LLC, Foresite Capital Management IV LLC, United Services Automobile Association, Casdin Capital LLC, Perceptive Advisors LLC and Foresite Capital Management III LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, June Lee, Marc Semigran and Sanofi. View Insider Buying and Selling for Myokardia.

Which institutional investors are buying Myokardia stock?

MYOK stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., BB Biotech AG, Orbimed Advisors LLC, Norges Bank, Samlyn Capital LLC, Polar Capital LLP, SG Americas Securities LLC and 361 Capital LLC. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos, Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia.

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $52.61.

How big of a company is Myokardia?

Myokardia has a market capitalization of $2.12 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-67,570,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

What is Myokardia's official website?

The official website for Myokardia is http://www.myokardia.com.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for Myokardia (NASDAQ MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel